Safety and efficacy of recombinant humanized monoclonal anti-VEGF [vascular endothelial growth factor] antibody rhuMaB VEGF [bevacizumab] and EGFR [epidermal growth factor receptor] tyrosine kinase inhibitor OSI-774 [erlotinib] for locally advanced or metastatic non-squamous cell NSCLC [non-small cell lung cancer] in patients who have been previously treated.

Trial Profile

Safety and efficacy of recombinant humanized monoclonal anti-VEGF [vascular endothelial growth factor] antibody rhuMaB VEGF [bevacizumab] and EGFR [epidermal growth factor receptor] tyrosine kinase inhibitor OSI-774 [erlotinib] for locally advanced or metastatic non-squamous cell NSCLC [non-small cell lung cancer] in patients who have been previously treated.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 24 Nov 2014

At a glance

  • Drugs Bevacizumab (Primary) ; Erlotinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 27 Oct 2009 Additional lead trial nvestigator, actual patient number (41) identified as reported by ClinicalTrials.gov.
    • 27 Oct 2009 Primary endpoint added as reported by ClinicalTrials.gov.
    • 08 Jan 2008 Status changed from suspended to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top